Skip to main content

Table 2 Risk of local failure, regional failure, distant failure, recurrence, and death according to levels of inflammatory blood markers

From: Different inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study

 

Pts

Local failure

Regional failure

Distant failure

Recurrence/Death

Death

 

HR (95% CI)a

Wald \(\chi\)2

HR (95% CI)a

Wald \(\chi\)2

HR (95% CI)a

Wald \(\chi\)2

HR (95% CI)

Wald \(\chi\)2

HR (95% CI)

Wald \(\chi\)2

Neutrophil-to-lymphocyte ratio (NLR)

 < 2.10

311

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

2.10 to < 3.76

406

0.97 (0.64–1.47)

p = 0.8815

1.76 (1.12–2.75)

p = 0.0139

1.14 (0.71–1.86)

p = 0.5813

1.05 (0.83–1.34)

p = 0.6739

1.05 (0.81–1.36)

p = 0.7063

 ≥ 3.76

208

1.15 (0.71–1.87)

p = 0.5733

1.82 (1.06–3.14)

p = 0.0303

1.37 (0.78–2.40)

p = 0.2710

1.47 (1.12–1.92)

p = 0.0048

1.39 (1.05–1.85)

p = 0.0231

Platelet-to-lymphocyte ratio (PLR)

 < 127.7

465

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

127.7 to < 162.8

228

0.87 (0.56–1.34)

p = 0.5267

1.52 (0.95–2.44)

p = 0.0808

0.83 (0.48–1.44)

p = 0.5089

1.15 (0.90–1.45)

p = 0.2629

1.17 (0.91–1.51)

p = 0.2251

 ≥ 162.8

232

1.44 (0.97–2.13)

p = 0.0718

1.98 (1.24–3.15)

p = 0.0043

1.67 (1.08–2.58)

p = 0.0208

1.35 (1.07–1.71)

p = 0.0111

1.30 (1.01–1.68)

p = 0.0413

Lymphocyte-to-monocyte ratio (LMR)b

 ≥ 4.28

188

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

2.92 to < 4.28

331

1.57 (0.87–2.86)

p = 0.1363

1.55 (0.86–2.81)

p = 0.1488

1.17 (0.62–2.19)

p = 0.6348

1.24 (0.92–1.68)

p = 0.1643

1.20 (0.87–1.67)

p = 0.2667

 < 2.92

405

2.16 (1.22–3.84)

p = 0.0087

1.89 (1.10–3.25)

p = 0.0220

1.44 (0.79–2.65)

p = 0.2348

1.58 (1.18–2.12)

p = 0.0021

1.52 (1.11–2.09)

p = 0.0098

Systemic inflammatory marker (SIM)b

 < 1.40

423

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

1.40 to < 2.46

295

1.00 (0.65–1.56)

p = 0.9861

1.32 (0.86–2.01)

p = 0.2046

1.60 (1.02–2.50)

p = 0.0400

1.14 (0.90–1.44)

p = 0.2727

1.20 (0.94–1.54)

p = 0.1463

 ≥ 2.46

206

1.42 (0.90–2.23)

p = 0.1277

1.57 (0.97–2.52)

p = 0.0655

1.26 (0.72–2.21)

p = 0.4160

1.48 (1.15–1.91)

p = 0.0024

1.43 (1.09–1.89)

p = 0.0099

Systemic immune-inflammation index (SII)

 < 602

501

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

602 to < 754

127

0.83 (0.49–1.42)

p = 0.5027

1.24 (0.72–2.14)

p = 0.4404

1.01 (0.55–1.86)

p = 0.9706

0.98 (0.74–1.31)

p = 0.8913

0.97 (0.71–1.32)

p = 0.8480

 ≥ 754

297

1.23 (0.85–1.79)

p = 0.2786

1.66 (1.10–2.51)

p = 0.0157

1.33 (0.87–2.02)

p = 0.1887

1.37 (1.11–1.70)

p = 0.0034

1.32 (1.05–1.66)

p = 0.0171

  1. Hazard ratio (HR) and corresponding 95% confidence interval (CI) were estimated through Cox proportional hazard model, adjusting for study centre, gender, age, cancer site, pT, pN, surgical margins, extranodal extension, and adjuvant (chemo) radiotherapy. Optimal biomarkers’ cut-offs were determined through iterative procedure which maximize predictability on overall survival
  2. aAdjusted for competing risk according to Fine and Gray model. bOne patients has missing data
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us